advertisement

Hungarian Investment and Trade Development Authority

33 %
67 %
advertisement
Information about Hungarian Investment and Trade Development Authority

Published on March 6, 2009

Author: gscouncil

Source: slideshare.net

Description

Presentation by Mr. Harskuti, representative of Hungarian Investment and Trade Development Authority, at Global Sourcing Council Conference at Stevens Institute of Technology
advertisement

 

Long t radition , n ew FDI into R&D National pharmaceutical industry with strong roots Strong presence of large international pharmaceutical and biotechnology companies: R&D and manufacturing

National pharmaceutical industry with strong roots

Strong presence of large international pharmaceutical and biotechnology companies:

R&D and manufacturing

WHY HUNGARY STRENGTHS AND OPPORTUNITIES IN THE HUNGARIAN PHARMA SECTOR O ne of the largest and most developed pharma markets in Eastern Europe; T he strongest pharma sector in terms of technology and productivity in Eastern Europe; EU harmonized pharma legislation; T he largest FDI stock in the pharma sector in the region ; E xpanding branded products market; G rowing pharma export

STRENGTHS AND OPPORTUNITIES IN

THE HUNGARIAN PHARMA SECTOR

O ne of the largest and most developed pharma markets in Eastern Europe;

T he strongest pharma sector in terms of technology and productivity in Eastern Europe;

EU harmonized pharma legislation;

T he largest FDI stock in the pharma sector in the region ;

E xpanding branded products market;

G rowing pharma export

Strong scientific and technological base of highly skilled workforce Large n umber of students in pharma related high education faculties Cost advantages: 30-50% of the EU wage level Well-trained researchers and scientists Lower o verhead costs Academic-Corporate cooperation Universities : Budapest, Szeged, Pécs, Debrecen, Gödöllő, Veszprém Main Research Centres : Agricultural Biotechnology Center, Gödöllő, Bay Zoltán Institute for Biotechnology, Szeged, Biological Research Center, Szeged, Institute for Small Animal Researches, Gödöllő, Central Food Research Institute, Budapest Added value of the pharma sector

Strong scientific and technological base of highly skilled workforce

Large n umber of students in pharma related high education faculties

Cost advantages: 30-50% of the EU wage level

Well-trained researchers and scientists

Lower o verhead costs

Academic-Corporate cooperation

Universities : Budapest, Szeged, Pécs, Debrecen, Gödöllő, Veszprém

Main Research Centres : Agricultural Biotechnology Center, Gödöllő, Bay Zoltán Institute for Biotechnology, Szeged, Biological Research Center, Szeged, Institute for Small Animal Researches, Gödöllő, Central Food Research Institute, Budapest

Hungary is the fifth largest medicine producer in Europe Largest biotechnology innovation and spin-off sector in CEE Extensive R+D cooperation U niversity biotechnology centres clustered in four academic towns Life sciences A High Performing Sector

Hungary is the fifth largest medicine producer in Europe

Largest biotechnology innovation and spin-off sector in CEE

Extensive R+D cooperation

U niversity biotechnology centres clustered in four academic towns

Latest investments in the life sciences sector 2005: Chinoin -Sanofi (F) : Establishment of a new R&D cent re in Budapest Teva Hungary (Israel) : Manufacturing active pharmaceutical components, Sajóbábony Icon Clinical Researc (Ireland) h : New R&D centre in Budapest Chinoin -Sanofi : Hypodermic syringe manufacturing plant + lab + warehouse in Csanyikvölgy. Planned capacity of 100million syringe per year. Richter Gedeon : Expanding and modernizing the capacity of the Dorog plant 2006: Chinoin-Sanofi : 2nd R&D center in Budapest Astellas Europe (Japan) : Establishment of a Hungarian sales office AIBMR Life Sciences (USA) : Establishment of a European office in Budapest. Synexus Clinical Res.(UK): Establishment of clinical research center , Budapest GlaxoSmithKline (UK) : Establishment of high-tech vaccine-manufacturing plant in Gödöllő . Servier-EGIS (F) : Establishment of chemical research lab. Teva Hungary : Establishment of logistics cent r e in Gödöllő .

2005:

Chinoin -Sanofi (F) : Establishment of a new R&D cent re in Budapest

Teva Hungary (Israel) : Manufacturing active pharmaceutical components,

Sajóbábony

Icon Clinical Researc (Ireland) h : New R&D centre in Budapest

Chinoin -Sanofi : Hypodermic syringe manufacturing plant + lab + warehouse in Csanyikvölgy. Planned capacity of 100million syringe per year.

Richter Gedeon : Expanding and modernizing the capacity of the Dorog plant

2006:

Chinoin-Sanofi : 2nd R&D center in Budapest

Astellas Europe (Japan) : Establishment of a Hungarian sales office

AIBMR Life Sciences (USA) : Establishment of a European office in Budapest.

Synexus Clinical Res.(UK): Establishment of clinical research center , Budapest

GlaxoSmithKline (UK) : Establishment of high-tech vaccine-manufacturing plant in Gödöllő .

Servier-EGIS (F) : Establishment of chemical research lab.

Teva Hungary : Establishment of logistics cent r e in Gödöllő .

2007 Beike Biotechnology : Chinese stem cell research project, Budapest St James (Malta) : hospital project in Budapest AAI Pharma : Representative office of the American pharma company Sauflon Pharmaceuticals (UK) : Contact lense factory near Budapest. Capacity: 100 million contact lenses/ year Pfizer (USA) : Logistics and dist r ibution centre in Budapest 2008 TEVA (Israel) : expansion of pharmaceuticals manufacturing capacity in Debrecen Richter Gedeon (H) : R&D in Budapest and Debrecen Latest investments in the life sciences sector

2007

Beike Biotechnology : Chinese stem cell research project, Budapest

St James (Malta) : hospital project in Budapest

AAI Pharma : Representative office of the American pharma company

Sauflon Pharmaceuticals (UK) : Contact lense factory near Budapest. Capacity: 100 million contact lenses/ year

Pfizer (USA) : Logistics and dist r ibution centre in Budapest

2008

TEVA (Israel) : expansion of pharmaceuticals manufacturing capacity in Debrecen

Richter Gedeon (H) : R&D in Budapest and Debrecen

Nanotechnology in Hungary Close to 50 research groups or institutes including 20 companies in nanotechnology research or manufacturing ; Innovative areas : automotive, consumer electronics, pharmaceuticals, plastic, cre r amics and light and heavy metals manufacturing : bio/chemical sensors medical instruments composite polymers laser -technology ceramics metallurgy thin-layer coating, surfaces

Close to 50 research groups or institutes including 20 companies in nanotechnology research or manufacturing ;

Innovative areas : automotive, consumer electronics, pharmaceuticals, plastic, cre r amics and light and heavy metals manufacturing :

bio/chemical sensors

medical instruments

composite polymers

laser -technology

ceramics

metallurgy

thin-layer coating, surfaces

Medical device manufacturing Significant tradition of scientific equipment manufacturing 200 manufacturers at present, production value: USD 300 million/year Major products : orthopedic appliances, X-ray generators, dental fittings, artificial body parts, electrodiagnostic apparatus, needles, syringes Most locally produced goods are exported : Germany is the main destination, Russia is still a significant market The market will expand 3% annually until 2012 to USD 900 million (USD 92/capita) Legal background is harmonized with the EU

Significant tradition of scientific equipment manufacturing

200 manufacturers at present, production value: USD 300 million/year

Major products : orthopedic appliances, X-ray generators, dental fittings, artificial body parts, electrodiagnostic apparatus, needles, syringes

Most locally produced goods are exported : Germany is the main destination, Russia is still a significant market

The market will expand 3% annually until 2012 to USD 900 million (USD 92/capita)

Legal background is harmonized with the EU

Clinical trials Hungary has a solid record of attracting and conducting international clinical trials O ver 250 clinical trials performed each year – an outstanding number compared to Hungary’s population. Reasons for conducting clinical trials in Hungary: Rapid and reliable recruitment of study population Investigators are motivated and qualified High Quality of Data Reasonable price advantage Qualification of local study monitors is above international average

Hungary has a solid record of attracting and conducting international clinical trials

O ver 250 clinical trials performed each year – an outstanding number compared to Hungary’s population.

Reasons for conducting clinical trials in Hungary:

Rapid and reliable recruitment of study population

Investigators are motivated and qualified

High Quality of Data

Reasonable price advantage

Qualification of local study monitors is above international average

Strong innovation capacity The World Economic Forum ranks Hungary 24 among 131 countries in terms of the quality of scientific research institutions Source: Global Comp e titiveness Report, World Economic Forum, 2006/ 2007 Ranking Country Switzerland 1 USA 2 Germany 5 France 19 Norway 21 Hungary 24 Czech Republic 30 Slovenia 33 Spain 49 China 56 Poland 64 Greece 76

The World Economic Forum ranks Hungary 24 among 131 countries in terms of the quality of scientific research institutions

Four life science clusters Budapest, Szeged, Debrecen, P é cs: large international pharmaceutical and biotechnology companies clustered around universities E nhance the cooperation of academia and business Coordinated by Universities Granted € 6.3 million each by the National Research and Technology Council Long-term programs (8-10 years) in basic and applied research Genomnanotech Knowledge Centre Neurobiological Knowledge Centre Cell Communication Knowledge Centre Infobionics Knowledge Centre Medipolis Knowledge Centre Debrecen Szeged Budapest Pécs

Budapest, Szeged,

Debrecen, P é cs: large

international

pharmaceutical and

biotechnology companies

clustered around

universities

E nhance the cooperation of

academia and business

Coordinated by Universities

Granted € 6.3 million each

by the National Research

and Technology Council

Long-term programs (8-10

years) in basic and applied

research

Competitive wages compared to Western Europe Source: Mercer, 2007

Regulatory system The EU membership strengthened the regulatory system which ensures a transparent operating environment ; Medicines Act (1999) : the national procedures are in line with EU directives ; Pharmaceutical market regulations 2005 ; Pharmaceutical Economy Act, June 2007 established medicine pricing in an auction process that sets prices based on the cheapest drug ; T he intellectual property regime is in compliance with international standards .

The EU membership strengthened the regulatory system which ensures a transparent operating environment ;

Medicines Act (1999) : the national procedures are in line with EU directives ;

Pharmaceutical market regulations 2005 ;

Pharmaceutical Economy Act, June 2007 established medicine pricing in an auction process that sets prices based on the cheapest drug ;

T he intellectual property regime is in compliance with international standards .

Add a comment

Related pages

Hungarian Investment and Trade Development Agency | The ...

The Hungarian Investment and Trade Development ... local authorities ... It also organised 118 events to promote foreign direct investment in Hungary, ...
Read more

Hungarian Investment Promotion Agency

Összehozzuk Önt a potenciális befektetőkkel. A tárgyalások során folyamatosan közvetítünk és kapcsolatot tartunk a felek között
Read more

Government Agencies | EUGO

Government Agencies; ... Hungarian Investment and Trade ... Business development. Hungarian Investment and Trade Agency offers small and medium sized ...
Read more

Hungarian Investment and Trade Agency - Hungary Government ...

Hungarian Investment and Trade ... Hungarian Investment and Trade Agency - Hungary ... Copyright © 2000-2016 Hong Kong Trade Development Council ...
Read more

UK Trade & Investment - GOV.UK

UK Trade & Investment. Our export services; Apply for export opportunities ; ... Managing Director, Policy and Network Development Iain Banfield.
Read more

About Us | SARIO, Slovak Investment and Trade Development ...

The Slovak Investment and Trade Development ... to increase the influx of foreign investment while promoting Slovak companies in their effort to ...
Read more

Hungarian Investment and Trade Development Agency ...

Hungarian Investment and Trade Development Agency. company research & investing information. Find executives and the latest company news.
Read more

UNITED NATIONS International Chamber of Commerce The world ...

Its main goals are to maximize the trade, investment and development ... An Investment Guide to Uganda ... of the Uganda Investment Authority ...
Read more

SARIO, Slovak Investment and Trade Development Agency

... Oasis of trade in Central Asia. ... New conditions for investment incentives at the least developed ... Corporate development; Contacts; Registration ...
Read more